Effects of apalutamide: A Synthesis of Findings from 4 Studies

  1. Home
  2. Effects of apalutamide
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of apalutamide: A Synthesis of Findings from 4 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of apalutamide: A Synthesis of Findings from 4 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Apalutamide is a unique androgen receptor (AR) antagonist used to treat castration-resistant prostate cancer (CRPC). 4 found that combining apalutamide with autophagy inhibitors may enhance the effectiveness of treatment in prostate cancer cells. 3 investigated the effects of lowering the apalutamide dosage on skin-related adverse events and castration-resistant prostate cancer (CRPC)-free survival in individuals with advanced prostate cancer. 1 researched the effect of aerosolized amiloride on cystic fibrosis patients, finding that it regulates excessive sodium absorption in the respiratory epithelium. 2 investigated the impact of apalutamide on low-risk prostate cancer, suggesting that it might lower attrition rates in active surveillance by downstaging low-grade tumors. These research findings suggest that apalutamide might be a helpful treatment option for prostate cancer, but further investigation into dosage, adverse effects, and combination therapies is required.

Benefits and Risks

Benefits Summary

Apalutamide shows promise as a potential treatment option for castration-resistant prostate cancer. It might also lower attrition rates in active surveillance for men with low-risk prostate cancer. Additionally, decreasing the dosage of apalutamide might reduce the risk of skin-related side effects.

Risks Summary

Skin-related adverse events, fatigue, and gastrointestinal issues are among the most common side effects of apalutamide. 3 suggests that lowering the apalutamide dosage might lessen skin-related side effects, but further investigation is required.

Comparison between studies

Common points of studies

All of these studies suggest that apalutamide has the potential to be a successful prostate cancer treatment option. Furthermore, they indicate that more research into apalutamide's use in combination therapies, dosage adjustments, and side effects is needed.

Differences between studies

The target diseases, treatment aims, and research methodologies used in these studies varied. While 4 focused on the effects of combining apalutamide with autophagy inhibitors, 3 studied the effects of lowering apalutamide dosages on side effects. 1 studied the effectiveness of amiloride for cystic fibrosis patients, which is not directly related to prostate cancer. 2 focused on how apalutamide affects attrition rates in active surveillance for low-risk prostate cancer patients.

Consistency and Contradictions in Results

These studies suggest that apalutamide might be a promising treatment option for prostate cancer, but more research is needed to arrive at consistent conclusions. While 3 found that reducing the dosage of apalutamide might lessen skin-related side effects, other research has not confirmed this finding.

Notes on Application in Daily Life

Apalutamide shows promise as a potential treatment option for prostate cancer, but further investigation into side effects, dosage, and combination therapies is needed. It is critical to use apalutamide at the appropriate dosage and as directed by a doctor.

Limitations of Current Research

These studies have limitations, including small sample sizes and a lack of information on long-term safety and efficacy. More research into apalutamide's dosage, combination therapies, and side effects is needed.

Future Research Directions

Future research should focus on the long-term safety and efficacy of apalutamide, finding the best dosages and combination therapies, and developing methods to prevent and manage side effects. Studies comparing apalutamide to other prostate cancer treatments are also necessary.

Conclusion

Apalutamide shows promise as a potential treatment option for prostate cancer, but further investigation is needed. It is critical to use apalutamide at the appropriate dosage and as directed by a doctor. More research on apalutamide is anticipated in the future.

Literature analysis of 4 papers
Positive Content
4
Neutral Content
0
Negative Content
0
Article Type
1
0
0
0
4
1.

Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis.

Author: HofmannT, SenierI, BittnerP, HülsG, SchwandtH J, LindemannH

Induces sputum expectoration
Normalizes sodium absorption

Amiloride is effective at inducing sputum expectoration in CF.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.

Author: SchweizerMichael T, TrueLawrence, GulatiRoman, ZhaoYibai, EllisWilliam, SchadeGeorge, MontgomeryBruce, GoyalSonia, NegaKatie, HakanssonAlexander K, LiuYang, DavicioniElai, PientaKenneth, NelsonPeter S, LinDaniel, WrightJonathan

Prostate cancer treatment

This study investigated the potential of apalutamide to decrease active surveillance attrition rates for men with lower-risk prostate cancer. The hypothesis was that apalutamide could downstage tumors, potentially delaying the need for active treatment.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

3.

Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study.

Author: OishiTakuya, HatakeyamaShingo, TabataRyuji, FujimoriDaiji, KawashimaYohei, TanakaRyuma, IshiiNoritaka, MiuraHikari, TanakaToshikazu, OkamotoTeppei, YamamotoHayato, YoneyamaTakahiro, HashimotoYasuhiro, SatoSatoshi, OhyamaChikara

Apalutamide dose reduction

This study evaluates the effects of apalutamide dose reduction on skin-related adverse events (AEs) and castration-resistant prostate cancer (CRPC)-free survival in patients with advanced prostate cancer (PC). It finds that apalutamide dose reduction was not significantly associated with the incidence of skin-related AEs. However, dose reduction in patients with small body sizes may alleviate skin-related AEs without sacrificing oncological outcomes.

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.

Author: EberliDaniel, KranzbühlerBenedikt, MortezaviAshkan, SulserTullio, SalemiSouzan

CRPC treatment

ARN-509, an androgen receptor antagonist, has been shown to induce autophagy in prostate cancer cells. This study explores the impact of combining ARN-509 with autophagy inhibitors as a potential approach to overcoming therapeutic resistance.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.